Report Name: Cipla Limited Company Profile – Overview, History, SWOT Analysis, Products/Services, Facts, Financials, Key Executives, Competitors, Tech Intelligence, IT Outsourcing, IT Management, Recent Developments and Strategy Evaluation
Cipla Limited Report – Publisher: Research Cosmos
Price Scheme of the Report:
Single User License – USD 150
Team License – USD 175
Corporate License – USD 250
Cipla Limited– Business Description:
Cipla Limited is engaged in the development, manufacture, and sale of pharmaceutical products. The company’s product portfolio comprises generic and complex APIs, respiratory products (metered dose inhalers (MDIs), dry powder inhalers, nasal sprays, nebulizers and a wide range of inhaled accessory devices), antiretrovirals (ARVs), antimalarial drugs, and veterinary products. It manufactures more than 2,000 products across 65 therapeutic categories in its 43 facilities.
The company operates through a single business segment: pharmaceutical. However, its operations can be categorized under four strategic business units: API, respiratory, Cipla Global Access (C-GA) and veterinary. The API business unit of Cipla manufactures more than 200 generic and complex APIs. This portfolio covers a range of therapeutic categories, including ARV, respiratory, metabolic disorder, gastrointestinal, oncology, antimalarial, and central nervous system, among others. In addition, Cipla has a robust pipeline of more than 50 APIs under various stages of development. The company’s respiratory business unit offers an extensive portfolio of inhalation products in more than 80countries worldwide.
Cipla’s inhalation products include MDIs, dry powder inhalers, nasal sprays, nebulizers and a range of inhaled accessory devices. It also offers other respiratory products such as spacers/holding chambers, which hold the medication for a few seconds after it has been released from the MDI. C-GA is a tender based institutional business that focusses on four major therapy areas: human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), malaria, multi drug-resistant tuberculosis (MDR TB), and reproductive health. C-GA business also develops and markets drugs for infections caused by helminths, schistosomiasis and kala azar, some of the major health threats in low and middle-income countries.
Cipla’s animal health division, Cipla Vet is one of the largest veterinary pharmaceutical exporters in India with a presence in more than 80countries. Cipla Vet specializes in equine and companion care. It also offers healthcare products for livestock, poultry, swine and marine animals. The company’s veterinary product range includes anti-infectives, anti-inflammatories, anti-thyroids, immunosuppressants, parasiticides, nutraceuticals and feed additives.
Geographically, India, Cipla’s largest geographical market, accounted for 40.7% of the total revenues in FY2017. Revenues from India reached INR59,529 million ($926.9 million) in FY2017, an increase of 8% over FY2016. The US accounted for 18.3% of the total revenues in FY2017. Revenues from the US reached INR26,750 million ($416.5 million) in FY2017, an increase of 29% over FY2016. South Africa accounted for 15.7% of the total revenues in FY2017. Revenues from South Africa reached INR23,008 million ($358.2 million) in FY2017, an increase of 44.3% over FY2016. Rest of the world accounted for 25.3% of the total revenues in FY2017. Revenues from rest of the world reached INR37,015.4 million ($576.7 million) in FY2017, a decrease of 19.7% over FY2016.
Scope of the Report:
About the Company: Historical Details, Current Ownership Structure and basic overview of Cipla Limited in terms of revenue, net income, and operating income.
Financials: Details about Cipla Limited listing status, annual financial reports (for the past 5 years), key financial highlights and region wise and category wise breakdown of their net revenue.
Products/Services: Listing of the company’s entire portfolio along with the description of individual products/services providing a clear picture of their target audience.
Company SWOT Analysis: Outlines’s strengths, weaknesses, and opportunities and threats facing the company.
Recent Developments: Showcases Cipla Limited’s recent developments including mergers, acquisitions, partnerships, collaborations, new product launches, investment and divestment plans.
Strategic Evaluation: This section provides an overview of Cipla Limited’s corporate goals and strategic initiatives and evaluates their outcomes along with outlining any persisting legal issues and outlook of our in-house analyst panel on the company.
Technology Landscape: Details how the company allocates its IT budget across the core areas of its business, CIO/CTO Profile, Key IT Initiatives and Deals undertaken by the company at present along with outlook.
Key Questions Answered
- What domain does Cipla Limited. operate and what are key points about it?
- What is the product/service portfolio of Cipla Limited?
- How has Cipla Limited performed financially from 2013?
- How does Cipla Limited rank among its peers in terms of revenue and market share?
- What is Cipla Limited strengths and weaknesses and what opportunities and threats do it face?
- What is Cipla Limited’s main growth strategies and how successful has the company been at implementing them?
- What is the in-house technical capability of Cipla Limited? Where does it procure/outsource it?
Reasons to buy
- Report delivered in easily accessible PPT format which can be used to gain insights quickly and further prepare presentations of your own
- Lean pricing structure ultimately giving you vast access to the unlimited knowledge repository of the company profiles at a very competitive cost
- 12 hour delivery time fulfilling your urgent requests as per your requirement
- On-demand customization options that can completely cater to your needs by focusing the report on given specifics
For More Information, Get Sample of the report: Request Sample
Got Some Questions? Inquire Here: Inquire Before Buying
Get This Report: Purchase Now
For More Details, Contact Provider Directly:
+1 888 709 8757